ELISA:OMXHEXElisa Oyj Class A Analysis
Data as of 2026-05-22 - not real-time
€41.70
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Elisa’s price is trading above its short‑term moving averages while the MACD shows a bullish crossover and the RSI sits in a neutral zone, indicating mixed short‑term momentum. The PE ratio sits above the industry average, suggesting the stock is priced for strong earnings that may be hard to deliver. Dividend yield is among the highest in the telecom sector, providing a compelling income component. Beta is exceptionally low, reflecting minimal sensitivity to broader market swings, yet volume has been decreasing, hinting at fading buying interest. Operating margins remain healthy, supporting solid cash generation, but revenue has slipped modestly year‑over‑year, limiting growth momentum.
The DCF fair‑value estimate lies well below the current market price, flagging a sizable valuation gap. The payout ratio approaches the upper limit of sustainability, raising questions about dividend durability. Analyst consensus points to limited upside, with price targets only marginally above current levels. Overall, investors face a trade‑off between an attractive dividend and an overvalued price amid modest growth prospects.
The DCF fair‑value estimate lies well below the current market price, flagging a sizable valuation gap. The payout ratio approaches the upper limit of sustainability, raising questions about dividend durability. Analyst consensus points to limited upside, with price targets only marginally above current levels. Overall, investors face a trade‑off between an attractive dividend and an overvalued price amid modest growth prospects.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near resistance with bullish MACD signal
- high dividend yield offering income appeal
- decreasing volume indicating reduced short‑term buying pressure
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- stable operating margins and positive free cash flow
- valuation gap between market price and DCF fair value
- modest revenue decline limiting growth
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- significant overvaluation relative to intrinsic value
- high payout ratio challenging dividend sustainability
- limited upside potential based on analyst price targets
Key Metrics & Analysis
Financial Health
Revenue Growth-1.30%
Profit Margin15.26%
P/E Ratio19.5
ROE25.17%
ROA8.59%
Debt/Equity115.75
P/B Ratio5.0
Op. Cash Flow€698.5M
Free Cash Flow€352.3M
Industry P/E17.0
Technical Analysis
TrendNeutral
RSI54.6
Support€40.02
Resistance€42.06
MA 20€41.08
MA 50€41.90
MA 200€41.49
MACDBullish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Fair Value€19.66
Target Price€42.24
Upside/Downside1.29%
GradeOvervalued
TypeValue
Dividend Yield5.79%
Risk Assessment
Beta0.00
Volatility15.57%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.